Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Neuroone Med Technologies Co (NMTC)

32 + Investors. Track Smart Money conviction in NMTC. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -5
Streak
1Q ▼
Buyers last Q
36%

Smart Money Signals — NMTC

Based on 32 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their NMTC positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 86% of 3.0Y peak

86% of all-time peak
32 funds currently hold this stock — 86% of the 3.0-year high of 37 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
🚀

Fast accumulation — +78% more funds vs a year ago

fund count last 6Q
+14 new funds entered over the past year (+78% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🔴

Heavy selling pressure — only 36% buying

12 buying21 selling
Last quarter: 21 funds sold vs only 12 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.
➡️

Steady new buyers — ~7 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 14 → 9 → 8 → 7. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
📌

Mixed — 31% long-term, 44% new

■ 31% conviction (2yr+) ■ 25% medium ■ 44% new
Of the 32 current holders: 10 (31%) held >2 years, 8 held 1–2 years, and 14 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
📊

Peak discovery — momentum slowing

4 → 14 → 9 → 8 → 7 new funds/Q
New funds entering each quarter: 14 → 9 → 8 → 7. NMTC is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Veteran-anchored — 41% veterans vs 50% newcomers

■ 41% veterans ■ 9% 1-2yr ■ 50% new
Entry-cohort mix of 32 holders: 13 (41%) are 2+ year veterans, 3 entered 1–2 years ago, and 16 (50%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 7% AUM from top-100

7% from top-100 AUM funds
9 of 31 holders rank in the top 100 by AUM, but together hold only 7% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
4.6
out of 10
Moderate Exit Risk
Exit risk score 4.6/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — NMTC

In 2026 Q1, 12 hedge funds were net buyers of NMTC (7 opened a new position, 5 added to an existing one), while 21 reduced or exited (9 trimmed, 12 sold completely) — a 36% buyer ratio, indicating net institutional distribution. Net fund flow last quarter: -5 funds (more exits than new entries). Total institutional holders: 32.

Hedge Fund Ownership: NMTC

How many hedge funds hold NMTC — quarterly history vs. share price
Quarterly hedge fund ownership of NMTC vs. share price

Market Analysis: NMTC

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: NMTC

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Neuroone Med Technologies Co (NMTC) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much NMTC has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 82d ago
NMTC
-29.4%
XLV
+1.9%

NMTC outperformed XLV by -31.3% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 37d ago
NMTC
-21.9%
XLV
+3.0%

Since the filing became public, NMTC outperformed XLV by -24.9% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

6 top-rated funds 0 high-conviction
Consensus
3.7
/ 10
breadth
×
Elite
0.1
/ 10
conviction
Hedge Fund Positioning: NMTC
32 + Investors

Track Smart Money conviction in NMTC. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 32 37 -13.51%
13F Shares 12M 13M -5.49%
Total Value $9M $10M -4.57%
New Positions 7 8 -1
Increased Positions 4 9 -5
Closed Positions 12 5 +7
Reduced Positions 9 9 -
Total Calls 1 2 -50.0%
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: NMTC

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

32 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in NMTC. Verified SEC 13F-HR filings.

QUARTER:
Top 25 NMTC holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Perkins Capital Management Inc 1.07% 1,473,000 $1.1M
2 Bleichroeder LP 0.54% 4,000,000 $3.1M
3 Bard Associates Inc 0.36% 1,840,498 $1.4M
4 Sio Capital Management, LLC 0.06% 496,614 $386K
5 Essex Investment Management Co LLC 0.03% 261,953 $203K
6 Arch Global Advisors, LLC 0.01% 17,434 $14K
7 United Community Bank 0.01% 20,000 $16K
8 Legato Capital Management LLC 0.00% 61,642 $48K
9 Revisor Wealth Management LLC 0.00% 19,580 $15K
10 Two Sigma Securities, LLC 0.00% 24,764 $19K
11 Princeton Global Asset Management LLC 0.00% 16,833 $13K
12 Belpointe Asset Management LLC 0.00% 75,000 $58K
13 Focus Financial Network, Inc. 0.00% 34,722 $27K
14 J.W. Cole Advisors, INC. 0.00% 36,000 $28K
15 Renaissance Technologies LLC 0.00% 655,446 $509K
16 XTX Topco Ltd 0.00% 43,283 $34K
17 Vanguard Fiduciary Trust Co 0.00% 292,081 $227K
18 Vanguard Capital Management LLC 0.00% 1,397,329 $1.1M
19 Citadel Advisors LLC 0.00% 101,500 $79K
20 Mariner, LLC 0.00% 10,420 $8K
21 Aqr Capital Management LLC 0.00% 10,420 $8K
22 LPL Financial LLC 0.00% 15,034 $12K
23 Quent Capital, LLC 0.00% 40 —
24 Morgan Stanley 0.00% 12,096 $9K
25 Osaic Holdings, INC. 0.00% 350 —
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Neuroone Med Technologies Co (NMTC)

What does the Smart Money Trend signal show for NMTC?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their NMTC positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for NMTC?

Heavy selling pressure — only 36% buying: Last quarter: 21 funds sold vs only 12 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

What is the fund quality score for NMTC holders?

Smaller funds dominant — 7% AUM from top-100: 9 of 31 holders rank in the top 100 by AUM, but together hold only 7% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held NMTC?

Mixed — 31% long-term, 44% new: Of the 32 current holders: 10 (31%) held >2 years, 8 held 1–2 years, and 14 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Neuroone Med Technologies Co (NMTC) following the 2026 Q1 hedge fund 13F filings?

As of today, NMTC has moved -21.9% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.0% for the XLV sector ETF — an outperformance of -24.9%. Since the quarter end (March 31, 2026), NMTC has gained -29.4% vs +1.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →